AR108844A1 - Proteínas de fusión y su aplicación en la preparación de vacunas - Google Patents
Proteínas de fusión y su aplicación en la preparación de vacunasInfo
- Publication number
- AR108844A1 AR108844A1 ARP170101706A ARP170101706A AR108844A1 AR 108844 A1 AR108844 A1 AR 108844A1 AR P170101706 A ARP170101706 A AR P170101706A AR P170101706 A ARP170101706 A AR P170101706A AR 108844 A1 AR108844 A1 AR 108844A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- fusion
- terminal end
- virus
- hepatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere a una proteína de fusión inmunogénica que comprende al menos los dos péptidos siguientes: a) en el extremo C-terminal, un primer péptido constituido: por la secuencia de aminoácidos de la proteína S o de la proteína M de una cepa aislada del virus humano de la hepatitis B (HBV), esta proteína S o proteína M es delecionada o no en su extremo N-terminal, y b) en el extremo N-terminal, un segundo péptido constituido: por la secuencia de aminoácidos de al menos un dominio transmembrana y del ectodominio de al menos una proteína de una cepa aislada del virus del Zika elegida entre la proteína de envoltura E o un péptido de fusión que comprende la proteína de envoltura E y la proteína prM. Reivindicación 9: Molécula de ácidos nucleicos que codifica una proteína de fusión según una cualquiera de las reivindicaciones 1 a 8. Reivindicación 11: Partícula subviral, no infecciosa e inmunogénica que comprende las proteínas siguientes: la proteína constituida por el dominio S nativo del antígeno de superficie de una cepa aislada del virus de la hepatitis B y al menos una proteína de fusión según una cualquiera de las reivindicaciones 1 a 8. Reivindicación 13: Proteína de fusión según una cualquiera de las reivindicaciones 1 a 8, para su utilización en la prevención y/o el tratamiento de la hepatitis B y/o de las infecciones ligadas al virus del Zika. Reivindicación 14: Una línea celular que expresa partículas subvirales, no infecciosas e inmunogénicas según la reivindicación 11.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1655677A FR3052779B1 (fr) | 2016-06-17 | 2016-06-17 | Nouvelles proteines de fusion et leur application pour la preparation de vaccins |
Publications (1)
Publication Number | Publication Date |
---|---|
AR108844A1 true AR108844A1 (es) | 2018-10-03 |
Family
ID=57233563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170101706A AR108844A1 (es) | 2016-06-17 | 2017-06-21 | Proteínas de fusión y su aplicación en la preparación de vacunas |
Country Status (6)
Country | Link |
---|---|
US (1) | US10766930B2 (es) |
EP (1) | EP3472182A1 (es) |
CN (1) | CN109715649A (es) |
AR (1) | AR108844A1 (es) |
FR (1) | FR3052779B1 (es) |
WO (1) | WO2017216505A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021232165A1 (en) * | 2020-05-22 | 2021-11-25 | University Of Saskatchewan | Recoded oncolytic viruses for treatment of cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2932388B1 (fr) * | 2008-06-17 | 2013-03-29 | Univ Rabelais Francois | Nouvelles proteines de fusion et leur application pour la preparation de vaccins contre l'hepatite c |
CN105821078A (zh) * | 2010-12-09 | 2016-08-03 | 巴斯德研究所 | 用于获得高产量重组蛋白表达的基于mgmt的方法 |
-
2016
- 2016-06-17 FR FR1655677A patent/FR3052779B1/fr not_active Expired - Fee Related
-
2017
- 2017-06-16 EP EP17740437.3A patent/EP3472182A1/fr not_active Withdrawn
- 2017-06-16 WO PCT/FR2017/051591 patent/WO2017216505A1/fr unknown
- 2017-06-16 US US16/310,666 patent/US10766930B2/en active Active
- 2017-06-16 CN CN201780038144.8A patent/CN109715649A/zh active Pending
- 2017-06-21 AR ARP170101706A patent/AR108844A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
FR3052779A1 (fr) | 2017-12-22 |
US10766930B2 (en) | 2020-09-08 |
US20190389912A1 (en) | 2019-12-26 |
EP3472182A1 (fr) | 2019-04-24 |
WO2017216505A1 (fr) | 2017-12-21 |
CN109715649A (zh) | 2019-05-03 |
FR3052779B1 (fr) | 2018-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR122964A2 (es) | Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
JP2016199557A5 (es) | ||
HRP20210608T1 (hr) | Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije | |
PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
AR092796A1 (es) | Composicion particulada de tipo viral | |
BR112017014219A2 (pt) | vacinas à base de nanopartículas multivalentes | |
WO2020063370A3 (zh) | 免疫组合物及其制备方法与应用 | |
CL2013003248A1 (es) | Composición inmunogenica que comprende una glucoproteina g de los virus hendra y nipah y un complejo inmunoestimulante; método para producir una respuesta de anticuerpo neutralizante contra un virus hendra y/o nipah en un sujeto. | |
PE20142330A1 (es) | Vacuna de peptido ch3 de ige | |
PE20120817A1 (es) | Peptidos tau antigenicos y usos de los mismos | |
EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
PE20120563A1 (es) | Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv | |
AR108781A1 (es) | Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv) | |
EA201892735A1 (ru) | Состав вакцины против hiv | |
WO2018224573A8 (en) | Recombinant measles virus expressing zika virus proteins and their applications | |
PE20240133A1 (es) | Vacuna de nanoparticula a base de proteinas contra metapneumovirus | |
WO2019006401A3 (en) | LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF | |
UY37198A (es) | Vacuna universal para enfermedades virales | |
PE20170429A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
BR112015032556A2 (pt) | Proteína matriz (m) modificada de um vírus da estomatite vesicular (vsv); sequência de nucleotídeos que codifica uma proteína matriz modificada de um vírus da estomatite vesicular; vírus da estomatite vesicular recombinante (rvsv); vacina; vacina de combinação de preparação e reforço; kit; peptídeo isolado; sequências de nucleotídeos isoladas; uso da vacina; uso da vacina de combinação de preparação e reforço; método para induzir uma resposta imunológica em um indivíduo | |
RU2015130287A (ru) | Адаптация вируса гриппа н5 к человеку | |
JP2016520534A5 (es) | ||
WO2018115509A3 (en) | New flavivirus vaccine | |
UY36616A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos | |
AR108844A1 (es) | Proteínas de fusión y su aplicación en la preparación de vacunas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |